• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].

作者信息

Löffler W, Gröbner W, Zöllner N

出版信息

Arzneimittelforschung. 1983;33(12):1687-91.

PMID:6686776
Abstract

The effects of a fixed combination of 100 mg allopurinol and 20 mg benzbromarone (Acifugan) on plasma and urinary uric acid were compared with those of 300 mg allopurinol alone during standardized dietary conditions (purine-free, isoenergetic formula diet with addition of 2 g ribonucleic acid per day). In addition, the components of the fixed combination were given separately. Diet and ribonucleic acid were taken by healthy volunteers for periods of 14 days, drugs were added from day 8 to day 14. Steady state uric acid values before and during drug ingestion were compared intraindividually to calculate drug effects. The fall of plasma uric acid was not significantly different during treatment with 300 mg allopurinol as compared with combined low dose treatment. Renal uric acid excretion was decreased by 56 and 23%, respectively. Comparing combined low dose treatment with the cumulative effects of its constituents it was found that combined treatment was less effective. With combined low dose treatment there is no need to observe prophylactic measures concerning complications at the site of the urinary tract. Compared with monotherapy with 300 mg allopurinol there is no advantage. However, the frequencies of side effects, which are not dose-dependent, will be cumulative with combined treatment, which is probably a major disadvantage. Combined treatment should not be used therefore with the exception of proven inefficiency of monotherapy.

摘要

相似文献

1
[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
Arzneimittelforschung. 1983;33(12):1687-91.
2
[Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].[低剂量降尿酸药物对高尿酸血症合并高甘油三酯血症患者的随机分组研究效应]
Fortschr Med. 1979 Jul 19;97(27):1212-4.
3
[The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].苯溴马隆泡腾颗粒与别嘌醇降尿酸作用的比较研究(作者译)
MMW Munch Med Wochenschr. 1978 Oct 20;120(42):1387-90.
4
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.与标准剂量的别嘌醇相比,低剂量别嘌醇与苯溴马隆联合使用对高尿酸血症的疗效。
J Med Assoc Thai. 2004 Sep;87(9):1087-91.
5
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.苯溴马隆与别嘌醇相比在降低高尿酸血症患者血清尿酸水平方面的疗效。
J Med Assoc Thai. 2002 Jun;85 Suppl 1:S40-7.
6
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].[别嘌醇与苯溴马隆单一及联合治疗。肾脏对致石物质和胶体保护物质的排泄(作者译)]
Med Klin. 1977 Apr 15;72(15):664-8.
7
Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine).别嘌醇对啤酒引起的嘌呤碱(尿酸、次黄嘌呤和黄嘌呤)血浆浓度升高及尿排泄的影响。
Horm Metab Res. 2006 Mar;38(3):188-92. doi: 10.1055/s-2006-925429.
8
[The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].苯溴马隆和丙磺舒在禁食条件下的促尿酸排泄作用(作者译)
Med Klin. 1978 Feb 17;73(7):240-6.
9
The pharmacology of hypouricemic effect of benzbromarone.苯溴马隆降尿酸作用的药理学
J Rheumatol. 1975 Dec;2(4):437-45.
10
[Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].[高尿酸血症与痛风的治疗。别嘌醇与苯溴马隆联合治疗的效果]
Fortschr Med. 1983 May 26;101(20):953-9.

引用本文的文献

1
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.预测痛风患者对降尿酸治疗的反应或无反应。
Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2.
2
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?苯溴马隆治疗痛风的获益-风险评估。其退市符合患者的最大利益吗?
Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002.
3
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
长期口服给药后别嘌醇和氧嘌呤醇的动力学。与苯溴马隆的相互作用。
Eur J Clin Pharmacol. 1986;31(1):53-8. doi: 10.1007/BF00870986.
4
[Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].[别嘌醇/苯溴马隆制剂对昼夜过程中尿液成分的影响]
Klin Wochenschr. 1987 Mar 2;65(5):218-24. doi: 10.1007/BF01715849.
5
[Differential indications for uricosuric drugs and allopurinol].
Klin Wochenschr. 1989 Mar 1;67(5):313-5. doi: 10.1007/BF01892902.
6
A study of dose-response relationships of allopurinol in the presence of low or high purine turnover.一项关于在嘌呤代谢转换率低或高的情况下别嘌呤醇剂量-反应关系的研究。
Klin Wochenschr. 1988 Feb 15;66(4):153-9. doi: 10.1007/BF01727784.
7
Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.吡嗪酰胺、丙磺舒和苯溴马隆对氧嘌呤醇肾排泄的影响。
Ann Rheum Dis. 1991 Sep;50(9):631-3. doi: 10.1136/ard.50.9.631.